Cat. No.
MABL-3701
Application
ELISA, FC, IHC
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
BIBH1 (Sibrotuzumab, huF19)
From
Recombinant Antibody
Specificity
This antibody binds specifically to human fibroblast activation protein (FAP). This protein is a cell surface glycoprotein serine protease that participates in extracellular matrix degradation and is involved in many cellular processes including tissue remodeling, fibrosis, wound healing, inflammation and tumor growth. This antibody does not cross react with rat, mouse, rabbit or cynomolgus monkey FAP.
Alternative Names
Seprase; Fibroblast activation protein; Prolyl endopeptidase FAP; 170 kDa melanoma membrane-bound gelatinase; Dipeptidyl peptidase FAP; FAPalpha; Fibroblast activation protein alpha; Gelatin degradation protease FAP; Integral membrane serine protease; Post-proline cleaving enzyme; Serine integral membrane protease; SIMP; Surface-expressed protease
UniProt
Q12884
Immunogen
The parental mouse antibody F19 was generated by immunizing mice with lung fibroblasts. The original humanized version of the antibody was generated by grafting of CDRs from the parental mouse antibody onto human framework regions.
Application Notes
The binding characterization of this antibody towards surface expressed FAP was done using flow cytometry. An in vitro assay with either human complement or with human MNC as effector mechanisms revealed no detectable cytotoxic effects on FAP-expressing tumor cell line HT-1080FAP clone33. This antibody was also used in the immunohistochemical analysis of normal and neoplastic human tissues. This antibody was also capable of binding recombinant human FAP in an ELISA (WO1999057151). A phase I biodistribution studywith 131I-labelled mAb F19 was carried out in 17 presurgical patients with hepatic metastases from colorectal cancer (PMID: 8201382). Another study investigated the anti-tumor activity, safety and pharmacokinetics of this antibody in patients with metastatic colorectal cancer. It concluded that this antibody was well tolerated and safe (PMID: 12624517).
Antibody First Published
Hofheinz et al. Stromal antigen targeting by a humanized monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie. 2003 Feb;26(1):44-8. PMID:12624517
Note on publication
This paper investigates the safety, anti-tumor activity and pharmacokinetics of sibrotuzumab (BIBH 1), a humanized version of murine anti-FAP mAb F19.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
